Home・Lista de Ações・Vir Biotechnology Inc

Vir Biotechnology Inc

Fechado

SetorSaúde

8.97 0.9

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

8.75

Máximo

9.02

Indicadores-chave
By Trading Economics
Rendimento	-83M -126M
Vendas	-64M -29K
EPS	-0.85
Margem de lucro	433,431.034
Funcionários	367
EBITDA	-83M -123M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+141.38% upside

Dividendos
By Acuity
Próximos Ganhos	4 de nov. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-140M 1.5B
Abertura anterior	8.07
Fecho anterior	8.97

Sentimento de Notícias

By Acuity

20%

80%

29 / 340 Ranking em Healthcare

Vir Biotechnology Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

10 de ago. de 2026, 23:56 UTC

Vir Biotechnology Inc. shares advanced in after-market trading, reflecting a modest increase from Monday's close, though still below the 20-day moving average.

7 de ago. de 2026, 19:36 UTC

Correlated Moves

Vir Biotechnology shares are higher, supported by broader market gains and a notable increase in the ARK Genomic Revolution ETF.

6 de ago. de 2026, 23:21 UTC

Vir Biotechnology Inc shares are higher in after-market trading, showing positive momentum following Thursday's close. No specific news was identified to explain the movement.

5 de ago. de 2026, 23:41 UTC

News

Social Media

Vir Biotechnology reported second-quarter revenue of $238.9 million, exceeding estimates, contributing to significant gains in after-market trading.

3 de ago. de 2026, 19:46 UTC

Vir Biotechnology Inc's shares are higher today, reflecting broader market trends amid falling oil prices. The stock remains below its 20-day moving average.

30 de jul. de 2026, 19:58 UTC

Vir Biotechnology Inc shares are higher today amid a broader recovery in tech stocks, despite breaking a recent trend of higher daily closes.

29 de jul. de 2026, 19:27 UTC

Shares of Vir Biotechnology Inc. are trading lower today, having declined after an initial uptick and hitting a session low in late morning.

28 de jul. de 2026, 15:46 UTC

Correlated Moves

Shares lower today, pressured by declines in biotech sector.

27 de jul. de 2026, 20:07 UTC

Vir Biotechnology's shares are higher today, continuing gains since Friday. The broader market is influenced by declining oil prices and lower Treasury yields.

25 de jul. de 2026, 00:01 UTC

Vir Biotechnology Inc shares are higher in after-market trading, recovering from earlier lows. The stock is near the lower end of its one-month trading range.

24 de jul. de 2026, 23:31 UTC

Vir Biotechnology Inc shares are higher in after-market trading, reflecting notable gains since Friday's close, despite no specific news driving the price action.

21 de jul. de 2026, 17:16 UTC

Correlated Moves

Vir Biotechnology Inc's shares are higher today, supported by a positive trend in the broader biotech sector. Earlier, shares pulled back but have since recovered.

20 de jul. de 2026, 21:02 UTC

Vir Biotechnology Inc shares fell during after-market hours amid broader market declines following a reported drop in the Leading Economic Index for June.

Comparação entre Pares

Variação de preço

Vir Biotechnology Inc Previsão

Preço-alvo

By TipRanks

141.38% parte superior

Previsão para 12 meses

Média 21.29 USD 141.38%

Máximo 30 USD

Mínimo 15 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Vir Biotechnology Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

8 ratings

Comprar

Manter

Vender

Com base em 8 analistas que deram avaliações de ações para Vir Biotechnology Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

29 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Vir Biotechnology Inc

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.